HLA相合同胞女性供者至男性受者移植中骨髓优于外周血干细胞
基于日本移植登记数据库分析1132例标准风险疾病患者,比较HLA相合同胞供者移植中外周血干细胞(PBSC)与骨髓(BM)的结局。在女性供者至男性受者(FtoM)移植中,PBSC组2年总生存(OS)和无复发死亡(NRM)均显著劣于BM组;在男性供者至女性受者(MtoF)及性别匹配移植中未见差异。多因素分析证实FtoM移植中PBSC对OS和NRM的不良影响。
核心结论
- 在FtoM移植中,使用PBSC与早期NRM风险增加相关,导致生存劣于BM。
- 当使用女性相关供者用于男性患者移植时,BM可能比PBSC获得更好的结局。
研究设计与样本
- 利用日本移植登记数据库,分析2013年至2016年间接受HLA相合同胞供者移植、无体内T细胞去除、标准风险疾病的1132例患者(FtoM n=315;MtoF n=260;性别匹配 n=557)。
- 分别在FtoM、MtoF和性别匹配移植中评估PBSC vs BM对移植结局的影响。
主要发现
- MtoF或性别匹配移植中,PBSC与BM组间未见差异。
- FtoM移植中,PBSC组患者频繁发生致命性GVHD和器官衰竭。
临床怎么用
- 在FtoM移植中,使用PBSC与早期NRM风险增加相关,导致生存劣于BM。
- 当使用女性相关供者用于男性患者移植时,BM可能比PBSC获得更好的结局。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (PBSCs) and sex-mismatched hematopoietic cell transplantation (HCT), especially with female donors and male recipients (FtoM), is known to be associated with an increased risk of chronic graft-versus-host disease (GVHD) compared with transplantation with bone marrow (BM). This raises the question of whether the use of PBSCs in FtoM HCT might affect allogeneic responses, resulting in fatal complications. Using a Japanese transplantation registry database, we analyzed 1132 patients (FtoM, n = 315; MtoF, n = 260; sex-matched, n = 557) with standard-risk diseases who underwent HCT with an HLA-matched related donor without in vivo T-cell depletion between 2013 and 2016. The impact of PBSC vs BM on transplantation outcomes was separately assessed in FtoM, MtoF, and sex-matched HCT. Overall survival (OS) and nonrelapse mortality (NRM) at 2 years post-HCT were significantly worse in patients with PBSCs vs those with BM in FtoM HCT (2-year OS, 76% vs 62%; P = .0084; 2-year NRM, 10% vs 21%; P = .0078); no differences were observed for MtoF or sex-matched HCT. Multivariate analyses confirmed the adverse impact of PBSCs in FtoM HCT (hazard ratio [HR] for OS, 1.91; P = .025; HR for NRM, 3.70; P = .0065). In FtoM HCT, patients with PBSCs frequently experienced fatal GVHD and organ failure. In conclusion, the use of PBSCs in FtoM HCT was associated with an increased risk of NRM in the early phase, resulting in inferior survival. This suggests that, when we use female-related donors for male patients in HCT, BM may result in better outcomes than PBSCs.
引用
- Nakasone H, Kawamura K, Yakushijin K, et al. BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. Blood Adv. 2019. PMID: 31182560. doi:10.1182/bloodadvances.2019000077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。